| Organism | Drug Class | Sponsor and/or Company | Drug Name | Alt Name | Drug Status | Notes | AIDS# |
| Plasmodium spp. | Antimalarial Aminoquinoline | Sanofi | Ferroquine | SR-97193 | Phase 2 | Terminated |
517288
|
| Plasmodium spp. | Antimalarial Endoperoxides | GlaxoSmithKline | Tafenoquine; Etaquine | WR 238605; SB-252263 | Phase 3 | Not Yet Recruiting |
006901
|
| Plasmodium spp. | Antimalarial Spiroindolone | Novartis | KAE-609 | NITD-609 | Phase 2 | Ongoing, Not Recruiting | |
| Plasmodium spp. | Antimalarial Trioxolane | Medicines for Malaria Venture | Artefenomel | OZ-439; MMV-08/1019 | Phase 2b | Recruiting | |
| Plasmodium spp. | Antimalarial aminopyridine | Medicines for Malaria Venture | MMV390048 | | Phase 1 | Recruiting | |
| Plasmodium spp. | Aspartic endopeptidase inhibitor | Actelion Pharmaceuticals | ACT-451840 | | Phase 1 | Recruiting | |
| Plasmodium spp. | Combination | Policlinique Medicale Universitaire | Cotrifazid | Rifampicin and Cotrimoxazole and Isoniazid | Phase 2 | Terminated | |
| Plasmodium spp. | Combination | Pfizer | Azithromycin and Chloroquine | AZCQ; Zithromax and Chloroquine; Zmax and Chloroquine | Phase 3 | Terminated | |
| Plasmodium spp. | Combination | Holley Pharm; Holleykin Pharm | Eurartesim; Artekin™; Duocotecxin™ | Dihydroartemisinin and Piperaquine | Phase 3 | Recruiting | |
| Plasmodium spp. | Combination | Jomma Pharma | Fosmidomycin-Piperaquine | | Phase 2a | Ongoing, Not Recruiting | |
| Plasmodium spp. | Combination | Jomaa Pharma | Fosclin; JP-01 | Clindamycin and Fosmidomycin | Phase 3 | Completed | |
| Plasmodium spp. | DNA Synthesis Inhibitor | Pfizer; Mission Pharmacal | Tindamax™; Fasigyn™; Simplotan™ | Tinidazole | Phase 2 | Completed |
007940
|
| Plasmodium spp. | Dihydroorotate dehydrogenase inhibitor | Medicines for Malaria Venture; Takeda | DSM265 | | Phase 2a | Recruiting | |
| Plasmodium spp. | Electron Transport Chain Inhibitor | GlaxoSmithKline | GSK932121 | | Phase 1 | Terminated | |
| Plasmodium spp. | Hemozoin Inhibitor | Tulane University Health Center | AQ-13 | Aminoquinoline | Phase 2 | Recruiting |
532415
|
| Plasmodium spp. | Inhibition of Phospholipid Metabolism | Sanofi-Aventis | SAR97276A | 1,12-Bis[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium]dodecane dibromide | Phase 2 | Terminated | |
| Toxoplasma gondii | Protein Synthesis Inhibitor (binds to 50S subunit) | Rhone-Poulenc Pharmaceuticals | Rovamycine™ | Spiramycin | Phase 3 | Recruiting |
007350
|
| Trypanosoma cruzi | Membrane Disruptor | Drugs for Neglected Diseases; Eisai Co., Ltd. | E1224 | Prodrug of Ravuconazole | Phase 2 | Unknown |
057176
|